CT
CytomX Therapeutics, Inc.
CTMX · NASDAQ
$3.65 +0.69% (+$0.02)
1M +6.10%
Market Cap $794.6M
P/E Ratio -
Div. Yield -
ROE 38.46%
Bulios Fair Price
$3.01
17.5% downside
Current Price
$3.65
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CTMX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
37 /100
Fair P/S 43.42x
P/B 2.63x
P/E N/A
Growth
78 /100
Growing Rev. growth 12.75%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 98.63%
Net margin 435.22%
Op. margin 476.19%
Quality
1 /100
Poor ROIC 25.49%
ROE 38.46%
ROA 20.89%
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 9.36x
Int. coverage N/A
Stability
1 /100
Unstable Beta 2.14x
Rev. volatility 68.06%
EPS volatility 2,920.99%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CTMX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sean A. McCarthy
Employees
69
Headquarters
South San Francisco
Upcoming events
05 NOV
Earnings
Upcoming earnings report